TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTORS
The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR...
Saved in:
Main Authors | , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
01.08.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain. |
---|---|
Bibliography: | Application Number: US202318529915 |